Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8347)
All Articles published online
|
Publishing Process of This Article
|
Oct 10, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol 2016; 7(5): 387-394 [PMID: 27777881 DOI: 10.5306/wjco.v7.i5.387] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v7/i5/387.htm |
| Number | Citing Articles |
| 1 |
Hongwei Yu, Xianqi Meng, Huang Chen, Xiaowei Han, Jingfan Fan, Wenwen Gao, Lei Du, Yue Chen, Yige Wang, Xiuxiu Liu, Lu Zhang, Guolin Ma, Jian Yang. Correlation Between Mammographic Radiomics Features and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00412
|
| 2 |
Jesse Lopes da Silva, Natalia Cristina Cardoso Nunes, Patricia Izetti, Guilherme Gomes de Mesquita, Andreia Cristina de Melo. Triple negative breast cancer: A thorough review of biomarkers. Critical Reviews in Oncology/Hematology 2020; 145: 102855 doi: 10.1016/j.critrevonc.2019.102855
|
| 3 |
Jing Lian, Hai-xia Ma, En-Wei Xu, Peng Bu, Ke-Ming Yun, Yan-Feng Xi. Subclassifying triple-negative breast cancers and its potential clinical utility. Virchows Archiv 2022; 481(1): 13 doi: 10.1007/s00428-022-03329-0
|
| 4 |
Willem H. Zoutman, Rogier J. Nell, Mieke Versluis, Ingrid Pico, T.H. Khanh Vu, Robert M. Verdijk, Mirjam van der Burg, Anton W. Langerak, Pieter A. van der Velden. A novel digital PCR-based method to quantify (switched) B cells reveals the extent of allelic involvement in different recombination processes in the IGH locus. Molecular Immunology 2022; 145: 109 doi: 10.1016/j.molimm.2022.03.003
|
| 5 |
Carlos A. Castaneda. Improving Oncology Worldwide. Sustainable Development Goals Series 2022; : 75 doi: 10.1007/978-3-030-96053-7_10
|
| 6 |
Anbok Lee, Kyu Yeoun Won, Sung-Jig Lim, Sun Young Cho, Sang-Ah Han, SaeGwang Park, Jeong-Yoon Song. ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer. Pathology - Research and Practice 2018; 214(5): 619 doi: 10.1016/j.prp.2018.04.006
|
| 7 |
Yan Wang, Suying Liu, Ying Zhang, Guanghui Zhu, Heping Wang, Bowen Xu, Yi Xie, Shuhan Yang. Effect of traditional Chinese medicine on postoperative depression of breast cancer: a systematic review and meta-analysis. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1019049
|
| 8 |
Ahmad Alhesa, Heyam Awad, Sarah Bloukh, Mahmoud Al-Balas, Mohammed El-Sadoni, Duaa Qattan, Bilal Azab, Tareq Saleh. PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy. International Journal of Immunopathology and Pharmacology 2022; 36 doi: 10.1177/03946320221078433
|
| 9 |
Sotiris Loizides, Anastasia Constantinidou. Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy. Frontiers in Genetics 2023; 13 doi: 10.3389/fgene.2022.1095839
|
| 10 |
Miao Ruan, Tian Tian, Jia Rao, Xiaoli Xu, Baohua Yu, Wentao Yang, Ruohong Shui. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. Diagnostic Pathology 2018; 13(1) doi: 10.1186/s13000-018-0743-7
|
| 11 |
Megan Fracol, Nikita Shah, David Dolivo, Seok Hong, Lexa Giragosian, Robert Galiano, Thomas Mustoe, John Y. S. Kim. Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement. Plastic & Reconstructive Surgery 2021; 148(2): 287 doi: 10.1097/PRS.0000000000008165
|
| 12 |
Christophe Van Berckelaer, Iris Vermeiren, Leonie Vercauteren, Charlotte Rypens, Gizem Oner, Xuan Bich Trinh, Wiebren A. A. Tjalma, Glenn Broeckx, Emmanuelle Charafe-Jauffret, Steven Van Laere, François Bertucci, Cecile Colpaert, Peter A. van Dam. The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers 2021; 13(18): 4656 doi: 10.3390/cancers13184656
|
| 13 |
Kelly E. Craven, Yesim Gökmen-Polar, Sunil S. Badve. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-83913-7
|
| 14 |
Sylvie Giacchetti, Lilith Faucheux, Charlotte Gardair, Caroline Cuvier, Anne de Roquancourt, Luca Campedel, David Groheux, Cedric de Bazelaire, Jacqueline Lehmann-Che, Catherine Miquel, Laurence Cahen Doidy, Malika Amellou, Isabelle Madelaine, Fabien Reyal, Laetitia Someil, Hamid Hocini, Christophe Hennequin, Luis Teixeira, Marc Espié, Sylvie Chevret, Vassili Soumelis, Anne-Sophie Hamy. Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy. Cancers 2022; 14(5): 1331 doi: 10.3390/cancers14051331
|
| 15 |
Javier Cuello-López, Ana Fidalgo-Zapata, Laura López-Agudelo, Elsa Vásquez-Trespalacios, Tomi F. Akinyemiju. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLOS ONE 2018; 13(11): e0207224 doi: 10.1371/journal.pone.0207224
|
| 16 |
Willem H. Zoutman, Rogier J. Nell, Pieter A. van der Velden. Cancer Immunosurveillance. Methods in Molecular Biology 2019; 1884: 1 doi: 10.1007/978-1-4939-8885-3_1
|
| 17 |
Rogier J. Nell, Willem H. Zoutman, Neus Calbet-Llopart, Adriana P. Garcia, Nino V. Menger, Mieke Versluis, Susana Puig, Nelleke A. Gruis, Pieter A. van der Velden. Accurate Quantification of T Cells in Copy Number Stable and Unstable DNA Samples Using Multiplex Digital PCR. The Journal of Molecular Diagnostics 2022; 24(1): 88 doi: 10.1016/j.jmoldx.2021.10.007
|
| 18 |
Nadine S. van den Ende, Anh H. Nguyen, Agnes Jager, Marleen Kok, Reno Debets, Carolien H. M. van Deurzen. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. International Journal of Molecular Sciences 2023; 24(3): 2969 doi: 10.3390/ijms24032969
|
| 19 |
Pooja M. Vaid, Anirudha K. Puntambekar, Nutan S. Jumle, Rituja A. Banale, Danish Ansari, Ruhi R. Reddy, Rohini R. Unde, Namrata P. Namewar, Devaki A. Kelkar, L. S. Shashidhara, Chaitanyanand B. Koppiker, Madhura D. Kulkarni. Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients. Diagnostic Pathology 2022; 17(1) doi: 10.1186/s13000-022-01271-y
|
| 20 |
Yajing Zhu, Evangelos Tzoras, Alexios Matikas, Jonas Bergh, Antonios Valachis, Ioannis Zerdes, Theodoros Foukakis. Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.999843
|
| 21 |
Tom van den Ende, Héctor G. van den Boorn, Nadine M. Hoonhout, Faridi S. van Etten-Jamaludin, Sybren L. Meijer, Sarah Derks, Tanja D. de Gruijl, Maarten F. Bijlsma, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020; 1874(1): 188386 doi: 10.1016/j.bbcan.2020.188386
|
| 22 |
Pierluigi De Santis, Martina Perrone, Chiara Guarini, Anna Natalizia Santoro, Carmelo Laface, Daniela Carrozzo, Gaia Rachele Oliva, Palma Fedele. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response. Exploration of Targeted Anti-tumor Therapy 2024; 5(1): 232 doi: 10.37349/etat.2024.00215
|
| 23 |
Ioannis Zerdes, Michele Simonetti, Alexios Matikas, Luuk Harbers, Balazs Acs, Ceren Boyaci, Ning Zhang, Dimitrios Salgkamis, Susanne Agartz, Pablo Moreno-Ruiz, Yalai Bai, David L. Rimm, Johan Hartman, Artur Mezheyeuski, Jonas Bergh, Nicola Crosetto, Theodoros Foukakis. Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. npj Breast Cancer 2021; 7(1) doi: 10.1038/s41523-021-00352-3
|
| 24 |
Tsengelmaa Jamiyan, Hajime Kuroda, Rin Yamaguchi, Yoshimasa Nakazato, Shuhei Noda, Masato Onozaki, Akihito Abe, Mitsuhiro Hayashi. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast. Breast Cancer 2020; 27(5): 880 doi: 10.1007/s12282-020-01084-1
|
| 25 |
Luca Campedel, Paul Blanc-Durand, Asker Bin Asker, Jacqueline Lehmann-Che, Caroline Cuvier, Cedric De Bazelaire, Luis Teixeira, Stephanie Becourt, Florence Ledoux, Hamid Hocini, Edwige Bourstyn, Catherine Miquel, Sophie Guillerm, Patrick Charveriat, Marc Espié, Anne De Roquancourt, Anne-Sophie Hamy, Sylvie Giacchetti. Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC. Cancers 2020; 12(9): 2657 doi: 10.3390/cancers12092657
|
| 26 |
In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung, Hee Jeong Kim, Sei Hyun Ahn, Hee Jin Lee, Gyungyub Gong. The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer. Cancer Research and Treatment 2022; 54(4): 1111 doi: 10.4143/crt.2021.1017
|
| 27 |
Carlos A. Huertas-Caro, Mayra A. Ramírez, Laura Rey-Vargas, Lina María Bejarano-Rivera, Diego Felipe Ballen, Marcela Nuñez, Juan Carlos Mejía, Luz Fernanda Sua-Villegas, Alicia Cock-Rada, Jovanny Zabaleta, Laura Fejerman, María Carolina Sanabria-Salas, Silvia J. Serrano-Gomez. Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-48300-4
|
| 28 |
Carlos Alexander Huertas-Caro, Mayra Alejandra Ramirez, Henry J. Gonzalez-Torres, María Carolina Sanabria-Salas, Silvia J. Serrano-Gómez. Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.910976
|
| 29 |
Victor Sarradin, Amélie Lusque, Thomas Filleron, Florence Dalenc, Camille Franchet. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. Breast Cancer Research 2021; 23(1) doi: 10.1186/s13058-021-01437-4
|
| 30 |
Zachary Gao, Sung Wook Kang, Derek Erstad, Joseph Azar, George Van Buren, William Fisher, Zequn Sun, Mark P. Rubinstein, Hyun-Sung Lee, E. Ramsay Camp. Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1274783
|
| 31 |
Kendall R. Clark, Wei Lue Tong, Blake M. Callahan, John M. Yavorski, Yaping N. Tu, George Blanck. TRB‐J1 usage, in combination with the HLA‐A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. International Journal of Immunogenetics 2019; 46(1): 31 doi: 10.1111/iji.12409
|
| 32 |
Yuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, Naoko Ishida, Kieko Yamazaki, Rie Horii, Yoshiya Horimoto, Norikazu Masuda, Hiroyuki Yasojima, Touko Inao, Tomofumi Osako, Masato Takahashi, Nobumoto Tomioka, Yumi Wanifuchi‑Endo, Mitsuchika Hosoda, Hiroyoshi Doihara, Hiroko Yamashita. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor‑positive/human epidermal growth factor receptor type 2 negative breast cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.9853
|
| 33 |
Dovile Zilenaite, Allan Rasmusson, Renaldas Augulis, Justinas Besusparis, Aida Laurinaviciene, Benoit Plancoulaine, Valerijus Ostapenko, Arvydas Laurinavicius. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00950
|
| 34 |
Hulya Sahin Ozkan, Mustafa Umit Ugurlu, Perran Fulden Yumuk, Handan Kaya. Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma. Pathology & Oncology Research 2020; 26(4): 2733 doi: 10.1007/s12253-020-00874-4
|
| 35 |
Triantafyllia Koletsa, Vassiliki Kotoula, Georgia-Angeliki Koliou, Kyriaki Manousou, Sofia Chrisafi, Flora Zagouri, Maria Sotiropoulou, George Pentheroudakis, Alexandra Papoudou-Bai, Christos Christodoulou, Grigorios Xepapadakis, George Zografos, Kalliopi Petraki, Elissavet Pazarli, Angelos Koutras, Helen P. Kourea, Dimitrios Bafaloukos, Kyriakos Chatzopoulos, Alexandros Iliadis, Christos Markopoulos, Vasileios Venizelos, Niki Arnogiannaki, Konstantine T. Kalogeras, Ioannis Kostopoulos, Helen Gogas, George Fountzilas. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunology, Immunotherapy 2020; 69(8): 1549 doi: 10.1007/s00262-020-02557-0
|
| 36 |
Jenny Stenström, Ingrid Hedenfalk, Catharina Hagerling. Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression. Breast Cancer Research 2021; 23(1) doi: 10.1186/s13058-021-01403-0
|
| 37 |
Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belén Pérez-Mies, Rodrigo Sánchez-Bayona, Luis Manso, Mario Martínez, Ana Garrido-García, Rosario Serrano-Pardo, Ramón Colomer, Miguel Quintela-Fandino. Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Clinical and Translational Oncology 2022; 25(4): 1124 doi: 10.1007/s12094-022-03006-3
|